Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name	Generic Name	Therapeutic Area	Recommendation Type	Project Status Sort descending	Date Submission Received	Date Recommendation Issued
Victoza	Liraglutide	Diabetes mellitus, Type 2	Do not list	Complete	Nov 29, 2010	Sep 28, 2011
Vimpat	Lacosamide	Epilepsy, partial onset seizures	List with clinical criteria and/or conditions	Complete	Oct 25, 2010	Apr 25, 2011
Pradaxa	Dabigatran etexilate	Atrial fibrillation prevention of stroke and systemic embolism	List with clinical criteria and/or conditions	Complete	Oct 28, 2010	Jun 22, 2011
VPRIV	Velaglucerase alfa	Gaucher Disease	List with clinical criteria and/or conditions	Complete	Oct 28, 2010	Apr 25, 2011
Daxas	Roflumilast	Chronic obstructive pulmonary disease	Do not list	Complete	Nov 30, 2010	Jul 27, 2011
Cayston	Aztreonam for inhalation solution	Cystic fibrosis, chronic pulmonary pseudomonas aeruginosa infections	List with clinical criteria and/or conditions	Complete	Dec 2, 2010	Jul 18, 2011
Restasis ophthalmic emulsion	Cyclosporine	Dry eye disease	Do not list	Complete	Dec 17, 2010	Jul 18, 2011
Celsentri	Maraviroc	HIV infection	Do not list	Complete	Dec 8, 2010	Jul 18, 2011
Nucynta CR	Tapentadol	Pain, moderate to moderately severe	Do not list	Complete	Feb 1, 2011	Sep 28, 2011
Zenhale (inhalation aerosol)	Mometasone furoate and formoterol	Asthma	Do not list	Complete	Feb 16, 2011	Sep 28, 2011

Last Updated : May 3, 2024